Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial.

Videla S, Lahjou M, Vaqué A, Sust M, Escriche M, Soler L, Sans A, Sicard E, Gascón N, Encina G, Plata-Salamán C.

Br J Clin Pharmacol. 2017 Sep 9. doi: 10.1111/bcp.13428. [Epub ahead of print]

PMID:
28888220
2.

Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects.

Videla S, Lahjou M, Vaqué A, Sust M, Encabo M, Soler L, Sans A, Sicard E, Gascón N, Encina G, Plata-Salamán C.

Br J Clin Pharmacol. 2017 Aug 15. doi: 10.1111/bcp.13395. [Epub ahead of print]

PMID:
28810061
3.

Next-day residual effects of flibanserin on simulated driving performance in premenopausal women.

Kay GG, Hochadel T, Sicard E, Natarajan KK, Kim NN.

Hum Psychopharmacol. 2017 Jul;32(4). doi: 10.1002/hup.2603. Epub 2017 May 31.

PMID:
28568608
4.

Evaluation of a Hybrid Training Module for Community Pharmacy Staff Providing Hypertension Medication Therapy Management.

Brown WI, Cernusca D, Roehrich L.

J Pharm Pract. 2017 Jan 1:897190017706637. doi: 10.1177/0897190017706637. [Epub ahead of print]

PMID:
28460560
5.

The 10th GCC Closed Forum: rejected data, GCP in bioanalysis, extract stability, BAV, processed batch acceptance, matrix stability, critical reagents, ELN and data integrity and counteracting fraud.

Cape S, Islam R, Nehls C, Allinson J, Safavi A, Bennett P, Hulse J, Beaver C, Khan M, Karnik S, Caturla MC, Lowes S, Iordachescu A, Silvestro L, Tayyem R, Shoup R, Mowery S, Keyhani A, Wakefield A, Li Y, Zimmer J, Torres J, Couerbe P, Khadang A, Bourdage J, Hughes N, Awaiye K, Matthews B, Fatmi S, Johnson R, Satterwhite C, Yu M, Lin J, Cojocaru L, Fiscella M, Thomas E, Kurylak K, Kamerud J, Lin ZJ, Garofolo W, Savoie N, Buonarati M, Boudreau N, Williard C, Liu Y, Warrino D, Kale P, Adcock N, Shekar R, O'Connor E, Ritzen H, Sanchez C, Hayes R, Bouhajib M, Savu SR, Stouffer B, Tabler E, Tu J, Briscoe C, der Strate BV, Rhyne P, Conliffe P, DuBey I, Yamashita J, Tang D, Groeber E, Vija J, Malone M, Osman M.

Bioanalysis. 2017 Apr;9(7):505-516. doi: 10.4155/bio-2017-5000. Epub 2017 Mar 24.

6.

Impact of telepharmacy services as a way to increase access to asthma care.

Brown W, Scott D, Friesner D, Schmitz T.

J Asthma. 2017 Jan 17:1-7. doi: 10.1080/02770903.2017.1281292. [Epub ahead of print]

PMID:
28095068
7.

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.

Kokai-Kun JF, Roberts T, Coughlin O, Sicard E, Rufiange M, Fedorak R, Carter C, Adams MH, Longstreth J, Whalen H, Sliman J.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02197-16. doi: 10.1128/AAC.02197-16. Print 2017 Mar.

8.

Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.

Rocha JF, Sicard É, Fauchoux N, Falcão A, Santos A, Loureiro AI, Pinto R, Bonifácio MJ, Nunes T, Almeida L, Soares-da-Silva P.

Br J Clin Pharmacol. 2017 Mar;83(3):540-553. doi: 10.1111/bcp.13156. Epub 2016 Dec 2.

PMID:
27763682
9.

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.

Fradette C, Pichette V, Sicard É, Stilman A, Jayashankar S, Tsang YC, Spino M, Tricta F.

Br J Clin Pharmacol. 2016 Oct;82(4):994-1001. doi: 10.1111/bcp.13037. Epub 2016 Jul 18.

11.

9th GCC closed forum: CAPA in regulated bioanalysis; method robustness, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, regulatory audit experiences and electronic laboratory notebooks.

Hayes R, LeLacheur R, Dumont I, Couerbe P, Safavi A, Islam R, Pattison C, Cape S, Rocci M, Briscoe C, Cojocaru L, Groeber E, Silvestro L, Bravo J, Shoup R, Verville M, Zimmer J, Caturla MC, Khadang A, Bourdage J, Hughes N, Fatmi S, Di Donato L, Sheldon C, Keyhani A, Satterwhite C, Yu M, Fiscella M, Hulse J, Lin ZJ, Garofolo W, Savoie N, Xiao YQ, Kurylak K, Harris S, Saxena M, Buonarati M, Lévesque A, Boudreau N, Lin J, Khan MU, Ray G, Liu Y, Xu A, Soni G, Ward I, Kingsley C, Ritzén H, Tabler E, Nicholson B, Bennett P, van de Merbel N, Karnik S, Bouhajib M, Wieling J, Mulvana D, Ingelse B, Allen M, Malone M, Fang X.

Bioanalysis. 2016 Mar;8(6):487-95. doi: 10.4155/bio.16.16. Epub 2016 Feb 26.

12.

Discovery of a novel trimebutine metabolite and its impact on N-desmethyltrimebutine quantification by LC-MS/MS.

Montpetit H, Ranger M, Colin P, Furtado M, Garofolo F.

Bioanalysis. 2015;7(8):1007-15. doi: 10.4155/bio.15.31.

PMID:
25966011
13.

Tuberculosis: A biosocial study of admissions to a children's sanatorium (1936-1954) in Stannington, Northumberland, England.

Roberts CA, Bernard MC.

Tuberculosis (Edinb). 2015 Jun;95 Suppl 1:S105-8. doi: 10.1016/j.tube.2015.02.012. Epub 2015 Feb 13.

PMID:
25747813
14.

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.

Gane EJ, Lim YS, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, Roberts S, Massetto B, Ye Z, Pflanz S, Garrison KL, Gaggar A, Mani Subramanian G, McHutchison JG, Kottilil S, Freilich B, Coffin CS, Cheng W, Kim YJ.

J Hepatol. 2015 Aug;63(2):320-8. doi: 10.1016/j.jhep.2015.02.037. Epub 2015 Feb 27.

PMID:
25733157
15.

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.

Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM, McHutchison JG, Gane EJ, Foster GR.

J Hepatol. 2015 Mar;62(3):533-40. doi: 10.1016/j.jhep.2014.10.035. Epub 2014 Oct 30.

PMID:
25450717
16.

The impact of new partial AUC parameters for evaluating the bioequivalence of prolonged-release formulations.

Boily M, Dussault C, Massicotte J, Guibord P, Lefebvre M.

Eur J Pharm Sci. 2015 Jan 23;66:70-7. doi: 10.1016/j.ejps.2014.10.001. Epub 2014 Oct 13.

PMID:
25312344
17.

Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.

Paquette JM, Rufiange M, Iovu Niculita M, Massicotte J, Lefebvre M, Colin P, Telmat A, Ranger M.

Clin Ther. 2014 Nov 1;36(11):1650-64. doi: 10.1016/j.clinthera.2014.08.005. Epub 2014 Sep 15.

PMID:
25224876
18.

Application of high-resolution MS in the quantification of a therapeutic monoclonal antibody in human plasma.

Mekhssian K, Mess JN, Garofolo F.

Bioanalysis. 2014;6(13):1767-79. doi: 10.4155/bio.14.111.

PMID:
25157484
19.

Elimination of isobaric interference and signal-to-noise ratio enhancement using on-line mobile phase filtration in liquid chromatography/tandem mass spectrometry.

Lahaie M, Youhnovski N, Furtado M, Garofolo F.

Rapid Commun Mass Spectrom. 2014 Apr 30;28(8):886-92. doi: 10.1002/rcm.6851.

PMID:
24623692
20.

Choosing the appropriate matrix to perform a scientifically meaningful lipemic plasma test in bioanalytical method validation.

Mayrand-Provencher L, Furtado M, Mess JN, Dumont I, Garofolo F.

Bioanalysis. 2014;6(12):1639-46. doi: 10.4155/bio.14.33. Epub 2014 Mar 12.

PMID:
24617519

Supplemental Content

Loading ...
Support Center